GWOXI ’s Subsidiary, Supermicro Biotech, Opens Hsinchu Science Park Facility to Capture Anti-Cancer Drug Market
GWOXI Stem Cell, a pioneering leader in stem cell biomedical technology in Asia, is now leveraging its core stem cell biomedical technology to comprehensively expand investments and build an integrated group structure, further extending its international business reach. Under the GWOXI Stem Cell Group, Supermicro Biotech Co., Ltd., founded by biomedical science PhDs and master’s graduates from Taiwan, Tsinghua, and Cheng universities, held the opening ceremony of its Hsinchu Science Park facility on August 8. GWOXI Stem Cell Chairman Zhuang Mingxi stated that, given the recent rapid growth of Taiwan’s biotech industry and the increasing demand for plant-based raw materials, the completion of Supermicro Biotech’s facility is expected to provide clients with high-specification, high-purity, and high-quality natural raw materials, further supporting the development of domestic biotech and new drug development companies.
The opening ceremony of Supermicro Biotech’s Hsinchu facility attracted a steady stream of distinguished guests, including Hsinchu County Deputy Magistrate Yang Wenke, Deputy Director of the Hsinchu Science Park Administration Xu Zengru, Director of National Chiao Tung University (NCTU) Industry-Academia Operations Center Huang Kuancheng, and Manager of NCTU Innovation Incubation Center Zheng Huixin. In his speech, Deputy Magistrate Yang emphasized that Supermicro Biotech can provide high-specification, high-purity, and high-quality natural plant raw materials, further aiding domestic biotech and new drug development. He also highlighted that the areas across the Touqian River—including Zhubei, Hsinchu Science Park, and NCTU—have already formed a complete domestic biotech industry ecosystem.
Director Huang Kuancheng of NCTU stated that NCTU will build a hospital on its Bo’ai campus in the future. Supermicro Biotech’s technology will facilitate NCTU’s medical collaborations, particularly as plant-based pharmaceuticals become a growing trend. The Supermicro company’s cell laboratory within NCTU’s incubation center will also serve as a key highlight for NCTU’s future comprehensive biotech ecosystem within the hospital.
Chairman Zhuang Mingxi noted that Supermicro Biotech has obtained multiple patents in China, Taiwan, and the United States by employing supercritical fluid technology to extract components from traditional Chinese medicinal herbs, which can be directly incorporated into cell membranes to support tissue growth. When applied to skin wounds, these natural growth factors can accelerate wound healing. With the activation of Supermicro Biotech’s Hsinchu Science Park facility, the company will be able to provide more refined raw materials to downstream pharmaceutical and health supplement biotech manufacturers, enhancing the competitiveness of the pharmaceutical and biotech industries while generating greater value and benefits.
